<DOC>
	<DOCNO>NCT00348530</DOCNO>
	<brief_summary>Accumulated clinical experimental data suggest dysfunctional coronary microcirculation play pivotal role progression heart failure despite optimal therapy use . Therefore , hypothesize improvement microvascular function calcium antagonist , verapamil may result additional clinical benefit . Thus , aim study compare effect treatment verapamil carvedilol long-term outcome stable , chronic heart failure secondary non-ischemic cardiomyopathy .</brief_summary>
	<brief_title>Carvedilol Versus Verapamil Chronic Heart Failure Secondary Non-Ischemic Cardiomyopathy</brief_title>
	<detailed_description>Heart failure , irrespective etiology may view progressive disorder initiate different event sustain multifaceted pathophysiological mechanism . Regardless nature initiate event optimized therapy use , loss functioning cardiac myocytes develop disease progress . One potential explanation progression pathological mechanism underlie disease antagonize enough currently use therapeutic strategy . Accordingly , impaired myocardial perfusion secondary microvascular dysfunction postulate play major role progression heart failure despite standard therapy heart failure ( 1 ) . It hypothesize diffuse subendocardial ischemia due alter coronary physiology may contribute global cardiac dysfunction see heart failure patient ( 2 ) . Accordingly , coronary endothelial dysfunction microvascular epicardial level patient acute-onset idiopathic dilate cardiomyopathy chronic congestive heart failure report ( 3,4 ) Thus , take mentioned account , improvement endothelial function diminish subendocardial ischemia calcium antagonist may promise term use drug therapy patient stable chronic heart failure . The previous randomize study ( 5 ) long-term pilot study support point view . 1 . Neglia D , Michelassi C , Trivieri MG , et al . Prognostic role myocardial blood flow impairment idiopathic leave ventricular dysfunction . Circulation 2002 ; 105:186-193 . 2 . Unverferth DV , Magorien RD , Lewis RP , et al . The role subendocardial ischemia perpetuate myocardial failure patient nonischemic congestive cardiomyopathy . Am Heart J 1983 ; 105:176-179 . 3 . Mathier MA , Rose GA , Fifer MA , et al . Coronary endothelial dysfunction patient acute-onset idiopathic dilate cardiomyopathy . J Am Coll Cardiol 1998 ; 32:216-224 . 4 . Chong AY , Blann AD , Patel J , et al . Endothelial dysfunction damage congestive heart failure . Relation flow-mediated dilation circulate endothelial cell , plasma index endothelial damage , brain natriuretic peptide . Circulation 2004 ; 110:1794-1798 . 5 . Figulla HR , Gietzen F , Zeymer U , et al . Diltiazem improve cardiac function exercise capacity patient idiopathic dilate cardiomyopathy . Results diltiazem dilate cardiomyopathy trial . Circulation 1996 ; 94:346-352 .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Heart Failure , Systolic</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Chronic heart failure ( NYHA II III ; LV ejection fraction , â‰¤ 35 % ) secondary nonischemic cardiomyopathy . Stable condition least 6 month enrollment conventional therapy ( betablockers , ACE inhibitor diuretic ) . improvement clinical status conventional therapy outpatient period precede hospitalization change narrow epicardial coronary artery coronary angiography , insulin dependent diabetes , valvular heart disease ( except relative mitral regurgitation ) , endocrine disease , lack write informed consent , significant renal liver disease , drug alcohol abuse , therapy steroid calcium blocker within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>Systolic heart failure ; Therapy ; Cardiomyopathy</keyword>
</DOC>